Search

Displaying results 7171 - 7180 of 10000 in total
  1. Drug

    Propyphenazone

    go.drugbank.com/drugs/DB13524
    Investigational

    Propyphenazone is a non-steroidal anti-inflammatory agent with analgesic effects.[A275063, A275068]

    Mixtures: DERMAN 300 MG/100 MG/50 MG KAŞE, 1 KAŞECategories: Non COX-2 selective NSAIDS, Heterocyclic Compounds, 1-Ring
  2. Drug

    SVV-001

    go.drugbank.com/drugs/DB06129
    Investigational

    SVV-001 is investigated for use/treatment in cancer/tumors and lung cancer. SVV-001 is a solid. … SVV-001 (Seneca Valley Virus) is a novel native picornavirus being developed as a systemically deliverable oncolytic virus for treatment of human cancers with neuroendocrine features.

  3. Drug

    Cyclic GMP

    go.drugbank.com/drugs/DB02315
    Experimental

    Cyclic guanosine monophosphate (Cyclic GMP) is a guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions. … It is a cellular regulatory agent and has been described as a second messenger.

    Categories: Heterocyclic Compounds, 2-RingSynonyms: 3',5'-cyclic GMP, Guanosine 3',5'-cyclic phosphate
  4. Drug

    Linaprazan glurate

    go.drugbank.com/drugs/DB21534
    Investigational

    Linaprazan glurate is a small molecule drug. The usage of the INN stem '-prazan' in the name indicates that Linaprazan glurate is a proton pump inhibitor, not dependent on acid activation. … Linaprazan glurate is under investigation in clinical trial NCT07037875 (A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due

  5. Drug

    ND7001

    go.drugbank.com/drugs/DB05142
    Experimental

    ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. … Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic phosphodiesterase. It is a new type of antidepressant drug with anxiolytic activity.

  6. Drug

    Surabgene lomparvovec

    go.drugbank.com/drugs/DB21780
    Investigational

    Surabgene Lomparvovec is a biologic drug. … Surabgene Lomparvovec is under investigation in clinical trial NCT07007065 (Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity

  7. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene. … Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757]

    Synonyms: AAV2/5-hPDE6B
  8. Drug

    VY-HTT01

    go.drugbank.com/drugs/DB16999
    Investigational

    VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. … VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.

  9. Drug

    RO7300490

    go.drugbank.com/drugs/DB17535
    Investigational

    RO7300490 is an investigational Fibroblast Activation Protein-α (FAP) targeted CD40 agonist. … RO7300490 is under investigation in clinical trial NCT04857138 (A Study to Evaluate Safety, Pharmacokinetics and Anti-tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in

    Synonyms: RO 7300490, RO-7300490
  10. Drug

    FB-825

    go.drugbank.com/drugs/DB17598
    Investigational

    FB-825 is an investigational humanized monoclonal antibody that targets the CεmX domain of the membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells. … It is currently being investigated for immune disorders, such as atopic dermatitis and hyperimmunoglobulin E syndrome (HIES).[A258448,L45743]

    Synonyms: Recombinant humanized immunoglobulin gamma 1 monoclonal antibody (mAb) directed against the CemX segment of human membrane-bound immunoglobulin E (mIgE)